





SIMULATING MTOR HYPERACTIVATING MUTATIONS TO UNDERSTAND FUNCTIONALLY SIGNIFICANT STRUCTURAL REARRANGEMENTS

**LAB MEETING
JULY 18, 2016**

MTOR IS AN ATYPICAL SERINE/THREONINE KINASE




MTOR FORMS THE CATALYTIC CORE OF TWO COMPLEXES




MTOR FORMS THE CATALYTIC CORE OF TWO COMPLEXES






MTORC1




MTORC2



MTORC1 CONTROLS A NUMBER OF IMPORTANT PROCESSES




MTOR MUTATIONS ACROSS CANCER TYPES




■ Mutation
 ■ Deletion
 ■ Amplification
 ■ Multiple alterations

MTOR MUTATIONS OCCUR THROUGHOUT THE PROTEIN




MTOR MUTATIONS ARE PREVALENT IN CLEAR CELL RENAL CELL CARCINOMA (CCRCC)


STANDARD OF CARE FOR CCRCC PATIENTS IS RAPALOG TREATMENT, BUT THERE IS NO MOLECULAR MECHANISM TO EXPLAIN HETEROGENOUS RESPONSE TO THESE TREATMENTS



MTOR MISSENSE MUTATIONS ARE HYPERACTIVATING




SOME DOUBLE MUTATION COMBINATIONS ARE COOPERATIVE






F1	F1	F2	F3	K1	K2	K3	K3	Cluster	Mutation
L1460P	C1483F	F1888L	T1977K	S2215F	L2230V	M2327I	R2505P	L1460P	F1
	-	+	+	+	+	+	-	C1483F	F1
		+	+	+	+	+	+	F1888L	F2
			+	+	+	+	+	T1977K	F3
				+	+	+	+	S2215F	K1
					+	-	-	L2230V	K2
						+	+	M2327I	K3
							-	R2505P	K3

-	No cooperativity
+	Cooperativity



CAN WE DISSECT DIFFERENT MECHANISMS OF ACTIVATION?



CAN WE DETECT LOCAL STRUCTURAL CHANGES IN THE MUTANTS?




CAN WE DETECT LOCAL STRUCTURAL CHANGES IN THE MUTANTS?




DO MUTANTS AFFECT DFG-IN VS. OUT CONFORMATION?








KINASE DOMAIN








KINASE+FAT DOMAIN










HYPERACTIVATING MUTATIONS MAY PERTURB POPULATION OF STRUCTURAL CONFORMATIONS




HYPERACTIVATING MUTATIONS MAY PERTURB POPULATION OF STRUCTURAL CONFORMATIONS



HYPERACTIVATING MUTATIONS MAY PERTURB POPULATION OF STRUCTURAL CONFORMATIONS




FUTURE DIRECTIONS: WHAT OTHER COORDINATES CAN WE LOOK AT TO DISSECT MECHANISMS OF ACTIVATION?





LOOK AT HYPOTHESES FOR REGULATION: **SUBSTRATE ACCESS** AND **HELIX PACKING** (SHOWN IN RED)



FUTURE DIRECTIONS: BUILD AN MSM OF WT MTOR FOR BOTH KINASE DOMAIN AND KINASE+FAT DOMAIN





FIRST PASS MTOR KINASE DOMAIN MSM



FIRST PASS MTOR KINASE DOMAIN MSM





FIRST PASS MTOR KINASE DOMAIN MSM





FIRST PASS MTOR KINASE DOMAIN MSM




FIRST PASS MTOR KINASE DOMAIN MSM



FIRST PASS MTOR KINASE DOMAIN MSM




CAN WE CHOOSE BETTER STARTING CONFIGURATIONS FOR LARGE LOOPS?



~2000 ITERATIONS OF SAMS




```
if __name__ == '__main__':  
    netcdf_filename = 'output.nc'  
  
    system = LoopSoftening(netcdf_filename=netcdf_filename)  
    system.exen_sampler.update_scheme = 'global-jump'  
    system.mcmc_sampler.nsteps = 5000  
    system.exen_sampler.locality = 10  
    system.sams_sampler.update_method = 'optimal'  
    niterations = 10000  
    system.sams_sampler.run(niterations)
```



FUTURE DIRECTIONS

- **IMPORTANT TO FIND GOOD PARAMETERS TO IDENTIFY ACTIVE CONFORMATIONS OF MOTOR**
 - **LOOKING AT PIKK-FAMILY OF KINASES MIGHT BE A GOOD PLACE TO START**
- **NEED TO BUILD A BETTER MSM FOR THE KINASE DOMAIN ALONE- WILL BE AIDED BY HAVING ALL OF MY DATA PRESENT**
- **NEED TO BUILD AN MSM+FAT DOMAIN MSM AND INVESTIGATE GOOD WAYS TO COMPARE MSMS FOR DIFFERENT CONSTRUCTS**
- **WORK ON CONVINCING SOMEONE TO ASSAY KINASE ACTIVITY FOR KINASE DOMAIN ALONE AND COMPARE TO KINASE+FAT CONSTRUCT**

ACKNOWLEDGEMENTS



CHODERA LAB // MSKCC


JOHN CHODERA
SONYA HANSON
GREGORY ROSS
PATRICK GRINAWAY
CHAYA STERN
BAS RUSTENBURG
JULIE BEHR
MEHTAP ISIK
RAFAL WIEWIORA
JOSH FASS
ANDREA RIZZI
LUCLENIE RODRIGUEZ

HSIEH LAB

JAMES HSIEH
JIANING XU

THESIS COMMITTEE

JAMES HSIEH
SARAT CHANDALAPATY
ROBERT ABEL



Cover story

Rapamycin's secrets unearthed

From its exotic origins to its revival as a potential antiaging compound, rapamycin continues to fascinate

BETHANY HALFORD, C&EN BOSTON

Easter Island, where the bacterium that makes rapamycin was first isolated, is most famous for the 887 ancient giant statues, called moai, that line its shores.



**COVER STORY OF CHEMICAL
AND ENGINEERING NEWS THIS
WEEK**